Your position:
m.limatoxi.com
>>
EN
>>
EN
>>
Formulation
>>
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
>> article
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
Editor:xuezhe Clicks:
0
Date:2022-8-17 10:04:12
Keyword:
FDA
Healthoo Information:
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
UserLogin
UserName：
Password：
The non-formal user may read the summary, the formal user can read the whole article。
please at once register the user of Heatlhoo.com
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName
Contact:
Title:
Mr.
Ms.
Password
Repeat password:
Mobile
Email
Verification code:
Company Name
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
Upadatinibs launch accelerated: Crohns disease has simultaneously subm...
FDA Breakthrough Therapy Designation for Topical Vitamin A Derivatives...
AstraZenecas Ultomiris Third Indication Approved by US FDA!
New Drugs Approved by FDA in February 2022
Nature: FDA Approval of New Drugs Sales Forecast in 2021
FDA cautions Aurobindo oral solids formulation facility
Nhwa received FDA warning Letter for 3 APIs
Lihua received import alert from FDA
Chuanning 4 APIs passed FDA authentication
Modern passed FDA examination
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
map
